U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Alcoholism: Developing Drugs for Treatment
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Alcoholism: Developing Drugs for Treatment February 2015

Draft

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2015-D-0152
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

The purpose of this guidance is to assist sponsors in the clinical development of drugs for the 20 treatment of alcoholism. There are many different terms, definitions, and diagnostic criteria that 21 have been used to describe this condition. However, in this guidance, we use the term 22 alcoholism to describe patients with alcohol use problems that would make them candidates for 23 treatment with medication. As the World Health Organization (WHO) notes,3 alcoholism is a 24 “term of long-standing use” and is “generally taken to refer to chronic continual drinking or 25 periodic consumption of alcohol which is characterized by impaired control over drinking, 26 frequent episodes of intoxication, and preoccupation with alcohol and the use of alcohol despite 27 adverse consequences.”


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2015-D-0152.

Back to Top